Ambu® Laryngeal Mask as an Intubation Conduit

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if the Ambu Laryngeal Mask can be used as an intubation conduit for endotracheal intubation.

Clinical Trial Description

The laryngeal mask airway (LMA) is an established supra-glottic device that provides better ventilation than traditional mask ventilation and is less invasive than endotracheal intubation. Being less invasive, it is commonly used for short elective surgical procedures. Its ability to be both easily and rapidly inserted also makes it useful as a rescue device in difficult and failed intubations. Being a supra-glottic device, the LMA does not protect patients from regurgitation and aspiration. Additionally, patients requiring alternative positions, such as prone or lateral, or those having surgery in the neck/head area are contra-indicated for LMA use due to risk of possible movement of the LMA, and therefore possible loss of airway patency. Thus, the LMA can be utilized as an intermediary method of airway management to endotracheal intubation.

The manufacturer of the reusable LMA-ClassicTM states that "the success rate of intubation through the standard LMA-ClassicTM is highly variable (30-93%)," whereas the success rate of the disposable version, LMA-UniqueTM, has been found to be only 21%1. An LMA specifically designed for intubation now exists and improves the success rate of intubation. The reusable LMA-FastrachTM or Intubating-LMATM (ILMA) is a rigid and anatomically curved airway tube. It is wide enough to accommodate 8.0 mm cuffed endotracheal tubes. Attached to the ILMA is a rigid handle to aid in one-handed insertion, removal, and adjustment. Success rates for intubating through the ILMA are 96.5% when inserted blindly and 100% with fiberoptic guidance2. No disposable version of the ILMA presently exists.

The Ambu® Laryngeal Mask (ALMA) is a new disposable laryngeal mask with an anatomical curve similar to the ILMA. The reasons for the use of disposable products can be many and varied. The residual risk of the transmission of germs and protein particles represents one indication. If supra-glottic airway devices are used electively or in emergencies, e.g. for HIV-positive patients or those infected with Creutzfeldt-Jacob disease, reuse of the products is not desirable. Disposable products, on the other hand, offer the benefit that the transmission of germs is avoided, and at the same time offer considerable economic advantages due to the much lower price of the product. The disposable ALMA has been proven as an effective and safe supra-glottic airway device3. Upon fiberoptic visualization through its shaft, the glottis was visualized 91.5% of the time, indicating that this device may be used as an intubation conduit. The purpose of this study is to determine if the ALMA is also safe and effective as an intubating conduit. The hypothesis is that the ALMA will perform as well as, if not better than the LMA-UniqueTM. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind

Related Conditions & MeSH terms

Intubation, Endotracheal

Clinical Trial Details

NCT number	NCT00272194
Study type	Interventional
Source	The University of Texas Health Science Center, Houston
Contact
Status	Completed
Phase	Phase 4
Start date	December 2005
Completion date	April 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00917033` - Tracheal Intubation of Morbidly Obese Patients. GlideScope Versus Direct Laryngoscopy	Phase 4
Completed	`NCT00378651` - Use of the Stethoscope to Confirm Breathing Tube Placement	N/A
Completed	`NCT00778219` - Comparison of Heart Rate Variability Among Tracheal Intubation Methods	N/A
Recruiting	`NCT02291640` - Pediatric Intubation Among Nursing	N/A
Recruiting	`NCT02291627` - Pediatric Intubation With Difficult Airway	N/A
Not yet recruiting	`NCT02293226` - Video-laryngoscopy During Chest Compression	N/A
Completed	`NCT02291653` - Pediatric Endotracheal Intubation	N/A
Completed	`NCT01865643` - A Comparison of Two GlideScope Intubation Techniques	N/A
Completed	`NCT01156233` - Tube Tip Position in Orally Intubated 0-4year Old Children: Assessment of the Precision of Two Clinical Techniques	N/A
Completed	`NCT00968058` - Leak Pressure of Uncuffed Pediatric Endotracheal Tubes	N/A
Completed	`NCT00349245` - Dexmedetomidine vs. Remifentanil for Sedation During AFI	Phase 4
Completed	`NCT00434720` - Comparison of GlideScope Specific Stylet to Malleable Stylet for GlideScope Intubation	N/A
Completed	`NCT05143606` - 3D Printed Model Simulator or Virtual Reality Software for Training Fiberoptic Intubation Skill	N/A
Completed	`NCT00178555` - Comparison of the Video and Macintosh Laryngoscope in Patients Who May be Difficult to Intubate	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.